McKesson posts strong Q2 with 8% revenue growth and 18% EPS jump, shares up 32% this year.

McKesson, the largest U.S. pharmaceutical distributor, reported an 8% revenue increase to $111 billion in Q2 fiscal 2027, driven by North American pharmaceutical sales and GLP-1 distribution. Operating profit rose 13% to $1.9 billion, and adjusted EPS jumped 18% to $11.68, with full-year EPS guidance up 19%. Institutional investors have shown strong support, pushing shares up 32% this year and 235.5% since May 2022. With solid sales and earnings growth, McKesson remains a compelling stock for investors seeking exposure to healthcare distribution.

McKesson shares have gained strong investor interest, with 69% of Pluang users buying the stock. The price stands at USD 1,069.40, slightly down 1.22% as of Nov 12, 2026 00:01 WIB.